Antibody Drug Conjugates Contract Manufacturing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Global ADC Contract Manufacturing Companies and the Market is Segmented by Linker (Cleavable Linker and Non-Cleavable Linker), Application (Myeloma, Lymphoma, Breast Cancer, and Other Applications), Phase (Clinical and Commercial), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers Values in USD Million for the Abovementioned Segments.

Antibody Drug Conjugates Contract Manufacturing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Antibody Drug Conjugates Contract Manufacturing Market Size

Antibody Drug Conjugates Contract Manufacturing Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 10.94 Billion
Market Size (2030) USD 39.99 Billion
CAGR (2025 - 2030) 29.60 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration High

Major Players

Antibody Drug Conjugates Contract Manufacturing Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Antibody Drug Conjugates Contract Manufacturing Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Antibody Drug Conjugates Contract Manufacturing Market Analysis

The Antibody Drug Conjugates Contract Manufacturing Market size is estimated at USD 10.94 billion in 2025, and is expected to reach USD 39.99 billion by 2030, at a CAGR of 29.6% during the forecast period (2025-2030).

The COVID-19 pandemic had an enormous influence on the healthcare domain, significantly disrupting the whole supply chain, from raw materials to production and delivery. An optimistic and conscious approach to the development of monoclonal antibodies and other ADCs was driven into the spotlight as potential treatments for COVID-19. The pandemic created a sturdy and quick reaction from scientists working for governments and industries to produce medicines and vaccines. As a consequence of the demand for effective medicines for the treatment of COVID-19, the global production of antibody-drug conjugates, vaccines, and other pharmaceuticals expanded. Besides, ADCs are more complex to manufacture, which is likely to create more demand for contract manufacturing organizations.

Antibody-drug conjugates are complex, potent biologics that offer significant potential to address critical diseases, including cancer. The clinical potential of these therapeutics is attributed to their ability to effectively target disease-associated cells while minimizing off-target toxicity. Notably, with time and advancements in research, scientists have further improved the design and development process for these therapies. This has resulted in the approval of four new ADCs in 2020. To date, the USFDA has approved 12 antibody-drug conjugates, and 100 are in development.

Also, as per the ADC Review in 2021, around 70% of antibody-drug conjugate projects are outsourced to contract development and manufacturing organizations (CDMOs), and with the continued expansion of the pipelines, this trend is likely to endure further. As more commercial products reach the market, there is an acute need for contract development and manufacturing organizations that know the way to execute late-stage studies to support the filing strategy. CMOs, with plans to support commercial-scale antibody-drug conjugate manufacturing by setting up processes to handle challenging supply chains by investing in facilities and processes to ensure security, quality, and efficiency, are expected to contribute to the growth of the market over the forecast period. Hence, given the anticipated growth in the demand for antibody-drug conjugates, the contract manufacturing market for antibody-drug conjugates is also expected to witness significant growth in the coming years.

Antibody Drug Conjugates Contract Manufacturing Industry Overview

The antibody-drug conjugates contract manufacturing market is fragmented in nature, with several regional as well as international players. Some companies currently dominating the market are Lonza Group, Piramal Pharma Solutions, Abbvie Inc., Novasep, Merck KGaA, Cambrex Corporation, Recipharm, Thermo Fisher Scientific Inc., Cerbios-Pharma SA, and Sterling Pharma Solutions.

To gain a competitive edge, companies are putting in noteworthy efforts and capital investments toward expanding their capabilities, thereby enhancing their respective service portfolios. Some firms have also established new facilities dedicated to the manufacturing of highly potent compounds. The field has also observed the establishment of various partnerships between drug developers and ADC manufacturers.

Antibody Drug Conjugates Contract Manufacturing Market Leaders

  1. Lonza Group

  2. Abbvie, Inc.

  3. Merck KGaA

  4. Cambrex Corporation

  5. Recipharm

  6. *Disclaimer: Major Players sorted in no particular order
Antibody-Drug Conjugates Contract Manufacturing Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Antibody Drug Conjugates Contract Manufacturing Market News

  • July 2022: WuXi XDC and AbTis signed a memorandum of understanding to form a partnership to develop and manufacture antibody-drug conjugates.
  • In February 2022: Piramal Pharma invested over USD 53.42 million for the expansion of its antibody-drug conjugate capabilities at the Grangemouth facility in Scotland and is investing in new active pharmaceutical ingredient infrastructure at its Morpeth facility in England.

Antibody Drug Conjugates Contract Manufacturing Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing burden of Cancer Cases
    • 4.2.2 Increasing R&D Activities Pertaining to Antibody Drug Conjugates
    • 4.2.3 Growing Demand for Biologic Therapy
  • 4.3 Market Restraints
    • 4.3.1 R&D and Production Challenges
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Linker
    • 5.1.1 Cleavable Linker
    • 5.1.2 Non-Cleavable Linker
  • 5.2 By Application
    • 5.2.1 Myeloma
    • 5.2.2 Lymphoma
    • 5.2.3 Breast cancer
    • 5.2.4 Other Applications
  • 5.3 By Phase
    • 5.3.1 Clinical
    • 5.3.2 Commercial
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Lonza Group
    • 6.1.2 Piramal Pharma Solutions
    • 6.1.3 Abbvie Inc.
    • 6.1.4 Novasep
    • 6.1.5 Merck KGaA
    • 6.1.6 Cambrex Corporation
    • 6.1.7 Recipharm
    • 6.1.8 Thermo Fisher Scientific Inc.
    • 6.1.9 Cerbios-Pharma SA
    • 6.1.10 Sterling Pharma Solutions
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Antibody Drug Conjugates Contract Manufacturing Industry Segmentation

Antibody-drug conjugates (ADC) are a class of biopharmaceuticals designed for cancer treatment that comprise an antibody that specifically targets a tumor antigen and a cytotoxic compound associated with a chemical linker. They are intended to allow the precise targeting of the cytotoxic compound to kill tumor cells while having a limited effect on healthy tissue. As ADCs are a novel class of biopharmaceuticals, the production of such complex products requires both chemical and biological know-how. Contract manufacturing organization provides technical knowledge in conjugation and linker creation, as well as solid platforms.

The antibody-drug conjugates contract manufacturing market is segmented by linker (cleavable linker and non-cleavable linker), application (myeloma, lymphoma, breast cancer, and other applications), phase (clinical and commercial), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers values in USD million for the abovementioned segments.

By Linker Cleavable Linker
Non-Cleavable Linker
By Application Myeloma
Lymphoma
Breast cancer
Other Applications
By Phase Clinical
Commercial
Geography North America United States
Canada
Mexico
Geography Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Geography Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Geography Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
Geography South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Antibody Drug Conjugates Contract Manufacturing Market Research FAQs

How big is the Antibody Drug Conjugates Contract Manufacturing Market?

The Antibody Drug Conjugates Contract Manufacturing Market size is expected to reach USD 10.94 billion in 2025 and grow at a CAGR of 29.60% to reach USD 39.99 billion by 2030.

What is the current Antibody Drug Conjugates Contract Manufacturing Market size?

In 2025, the Antibody Drug Conjugates Contract Manufacturing Market size is expected to reach USD 10.94 billion.

Who are the key players in Antibody Drug Conjugates Contract Manufacturing Market?

Lonza Group, Abbvie, Inc., Merck KGaA, Cambrex Corporation and Recipharm are the major companies operating in the Antibody Drug Conjugates Contract Manufacturing Market.

Which is the fastest growing region in Antibody Drug Conjugates Contract Manufacturing Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Antibody Drug Conjugates Contract Manufacturing Market?

In 2025, the North America accounts for the largest market share in Antibody Drug Conjugates Contract Manufacturing Market.

What years does this Antibody Drug Conjugates Contract Manufacturing Market cover, and what was the market size in 2024?

In 2024, the Antibody Drug Conjugates Contract Manufacturing Market size was estimated at USD 7.70 billion. The report covers the Antibody Drug Conjugates Contract Manufacturing Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Antibody Drug Conjugates Contract Manufacturing Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Antibody Drug Conjugates Contract Manufacturing Industry Report

Statistics for the 2025 Antibody Drug Conjugates Contract Manufacturing market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Antibody Drug Conjugates Contract Manufacturing analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.